SLC7A11的调控机制及肿瘤治疗应用研究进展  

Regulatory Mechanism of SLC7A11 and Its Applications in Cancer Treatment

作　　者：刘晓轩 张驰 黄思琪 张玉超 钟鹏英 陈思雅 孔雨朦 蔡煜涵 刘文龙[1] 张喜利[1] LIU Xiaoxuan;ZHANG Chi;HUANG Siqi;ZHANG Yuchao;ZHONG Pengying;CHEN Siya;KONG Yumeng;CAI Yuhan;LIU Wenlong;ZHANG Xili(School of Pharmacy,Hunan University of Chinese Medicine,Changsha 410208,China;The First Affiliated Hospital of Hunan University of Chinese Medicine,Changsha 410208,China;The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine,Changsha 410208,China)

机构地区：[1]湖南中医药大学药学院,湖南长沙410208 [2]湖南中医药大学第一附属医院,湖南长沙410208 [3]湖南省中医药研究院附属医院,湖南长沙410208

出　　处：《中国肿瘤》2023年第11期878-885,共8页China Cancer

摘　　要：胱氨酸/谷氨酸逆向转运蛋白SLC7A11(也称为xCT)可介导细胞外胱氨酸的摄取以换取谷氨酸。胱氨酸被还原为谷胱甘肽合成的限速前体半胱氨酸,这一过程保护细胞免受氧化应激,因此对细胞生长、增殖和新陈代谢至关重要。由于SLC7A11的特殊结构功能,其参与到了铁死亡的启动过程中。因此,SLC7A11可能成为临床治疗癌症的潜在靶点。目前已有研究通过各种SLC7A11调节剂来调节SLC7A11的表达或活性以实现对铁死亡的调节,从而影响肿瘤微环境、免疫逃逸、肿瘤进程、化疗耐药以及肿瘤靶向治疗。全文就SLC7A11的调控机制及肿瘤治疗应用做一综述,以期为肿瘤治疗提供新思路。The cystine/glutamate transporter SLC7A11(also known as xCT)mediates the uptake of extracellular cystine in exchange for glutamate.Cysteine reduced from cystine is a rate-limiting precursor of glutathione synthesis,which protects cells from oxidative stress and is therefore essen-tial for cell growth,proliferation and metabolism.SLC7A11 is involved in the initiation of ferrop-tosis due to its specific structure and function.Studies have shown that the expression or activity of SLC7A11 can be regulated by various SLC7A11 modulators to induce cell ferroptosis,affecting tumor microenvironment,immune escape,tumour progression and chemotherapy resistance,indi-cating that SLC7A11 may be a potential target for treatment of malignant tumors.This paper re-views the regulatory mechanisms of SLC7A11 and its potential application in tumor therapy.

关 键 词：逆向转运蛋白 溶质载体家族7成员11 氧化应激 铁死亡 调控机制 肿瘤治疗 

分 类 号：R73[医药卫生—肿瘤]